Trial Profile
Phase II Trial of Maintenance Apatinib After Second-Line Treatment for Locally Recurrent or Metastatic Nasopharyngeal Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jun 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 27 May 2021 Status changed from active, no longer recruiting to completed.
- 27 May 2021 Results published in the Cancer
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology